Document is current
Any future updates will be listed below
-
Authors
Neiman, Gabriel https://orcid.org/0000-0003-1003-1559
Costa, Mauro W. https://orcid.org/0000-0003-3579-8625
Han, Hesong https://orcid.org/0000-0001-5545-5238
Zhao, Sheng https://orcid.org/0009-0002-9890-048X
K. Ng, Tammy https://orcid.org/0000-0003-1338-0025
Siemons, Brian
Nishino, Tomohiro https://orcid.org/0000-0002-3593-7368
Huang, Yu
Lal, Shyam
Wu, Kenneth
M. Judge, Luke
R. Conklin, Bruce
Srivastava, Deepak https://orcid.org/0000-0002-3480-5953
Murthy, Niren https://orcid.org/0000-0002-7815-7337
Healy, Kevin E. https://orcid.org/0000-0002-8524-3671
-
Funding
Funding for this research was provided by:
California Institute for Regenerative Medicine (DISC2-14045)
California Institute for Regenerative Medicine (DISC2-14045)
California Institute for Regenerative Medicine (DISC2-14045)
California Institute for Regenerative Medicine (DISC2-14045)
California Institute for Regenerative Medicine (DISC2-14045)
California Institute for Regenerative Medicine (DISC2-14045)
California Institute for Regenerative Medicine (DISC2-14045)
California Institute for Regenerative Medicine (DISC2-14045)
California Institute for Regenerative Medicine (DISC2-14045)
Agilent Technologies
- License Information
-
More Information
Article History
Received: 28 February 2024
Accepted: 29 August 2025
First Online: 3 November 2025
Competing interests
: K.E.H. and B.S. have a financial relationship with Organos Inc., and hence may benefit from the commercialization of the results of this research. N.M. and H.H. have a financial relationship in Opus Biosciences, and may benefit from the commercialization of the results of this research. D.S. is a scientific co-founder, shareholder and director of Tenaya Therapeutics. The other authors declare no competing interests.
